arXiv · 0808.0359
Some notable properties of the standard oncology phase I design
Abstract
We identify three properties of the standard oncology phase I trial design or 3 + 3 design. We show that the standard design implicitly uses isotonic regression to estimate a maximum tolerated dose. We next illustrate the relationship between the standard design and a Bayesian design proposed by Ji et al. (2007). A slight modification to this Bayesian design, under a particular model specification, would assign treatments in a manner identical to the standard design. We finally present calculations revealing the behavior of the standard design in a worst case scenario and compare its behavior with other 3 + 3-like designs.
Explore related subjects
Keep this discovery
Gregory J. Hather, Howard Mackey. 2009-06-07. Some notable properties of the standard oncology phase I design. https://arxiv.org/abs/0808.0359
Cite the original work for its findings. Save a collection to share your selection of sources.